70 results on '"Brandimarte, G."'
Search Results
2. T01.01.14 THE ROLE OF A NON-INVASIVE TEST IN THE MANAGEMENT OF UPPER-GI DISEASES: COMPARISON BETWEEN SEROLOGY AND ENDOSCOPIC FINDINGS IN A SAMPLE OF 3,795 PATIENTS
3. OC.08.3 THE “DICA” ENDOSCOPIC CLASSIFICATION FOR DIVERTICULAR DISEASE OF THE COLON SHOWS A SIGNIFICANT INTEROBSERVER AGREEMENT AMONG COMMUNITY ENDOSCOPISTS: AN INTERNATIONAL STUDY
4. T04.01.12 USEFULNESS OF FECAL CALPROTECTIN IN PRIMARY CARE SETTING: AN EXPERIENCE IN NORTH – EAST ITALY POPULATION
5. T01.01.24 RISK FACTORS OF EARLY AND ADVANCED GASTRIC CANCER: A 8 YEARS POPULATION STUDY IN NORTHERN ITALY
6. T02.01.7 IS HELICOBACTER PYLORI CURE A LONG-LIFE STRATEGY? A 25 YEARS SURVEY ON 693 PATIENTS
7. T01.02.17 CLINICAL USEFULNESS OF SECOND-GENERATION BARRIER DRUGS IN GERD PATIENTS WITH ATYPICAL SYMPTOMS: A-6-MONTHS PROSPECTIVE STUDY
8. T01.02.23 ROLE OF ENVIRONMENTAL FACTORS ON THE OUTCOME OF GASTROESOPHAGEAL REFLUX DISEASE: 6 MONTHS PROSPECTIVE STUDY
9. T01.02.19 IS IT POSSIBILE TO WITHDRAW PPIS THERAPY IN GERD PATIENTS? A PROSPECTIVE STUDY ON 216 PATIENTS USING A SECOND GENARTION BARRIER DRUG
10. OC.08.6 USEFULNESS OF FECAL CALPROTECTIN IN PRIMARY CARE: NON-INVASIVE APPROACH FOR THE FRAMING OF INTESTINAL DISEASES
11. T04.02.15 OCCURRENCE OF DIVERTICULAR DISEASE IN COLORECTAL CANCER SCREENING: A 3-YEAR STUDY ON 2,104 PATIENTS
12. T01.01.16 CORRELATION BETWEEN SERUM GASTRIC BIOMARKERS AND HISTOLOGICAL PICTURES OF H. PYLORI INFECTION AND ATROPHIC GASTRITIS: A POPULATION STUDY ON 1,122 PATIENTS
13. OC.08.4 RISK FACTORS FOR ENDOSCOPIC SEVERITY OF DIVERTICULAR DISEASE OF THE COLON AND ITS OUTCOME: A REAL-LIFE CASE-CONTROL STUDY
14. P.02.12 PREDICTIVE VALUE OF THE “DICA” ENDOSCOPIC CLASSIFICATION ON THE OUTCOME OF DIVERTICULAR DISEASE OF THE COLON: A 1-YEAR ANALYSIS FROM THE INTERNATIONAL, MULTICENTER, PROSPECTIVE STUDY
15. P.02.29 LONG-TERM EFFICACY OF RIFAXIMIN TO MANAGE THE SYMPTOMATIC UNCOMPLICATED DIVERTICULAR DISEASE OF THE COLON
16. P.02.25 RISK FACTORS FOR COLONIC DIVERTICULOSIS: A STUDY IN PRIMARY CARE SETTING
17. P.01.31 A COMPARISON OF DIFFERENT TREATMENTS FOR SYMPTOMATIC REFLUX ESOPHAGITIS: A REAL-LIFE STUDY
18. OC.05.6 THE PROGNOSTIC VALUE OF A NEW ENDOSCOPIC CLASSIFICATION FOR DIVERTICULAR DISEASE: DICA (DIVERTICULAR INFLAMMATION AND COMPLICATION ASSESSMENT)
19. OC.03.3 THE “DICA” ENDOSCOPIC CLASSIFICATION FOR DIVERTICULAR DISEASE OF THE COLON SHOWS A SIGNIFICANT INTEROBSERVER AGREEMENT AMONG COMMUNITY ENDOSCOPISTS
20. P.06.10 NATURAL HISTORY OF GASTRIC ULCER IN A 25 YEARS FOLLOW-UP: ROLE OF HELICOBACTER PYLORI INFECTION AND NONSTEROIDAL ANTI-INFLAMMATORY DRUGS
21. P.01.22 REFLUX ESOPHAGITIS AFTER H.P. ERADICATION: THE ROLE OF GASTRIC ACID SECRETION
22. P.01.29 GASTRIC ULCER: RISK FACTORS, HELICOBACTER PYLORI INFECTION AND NSAIDS USE IN A SAMPLE OF 256 PEOPLE
23. OC.03.4 IMPACT OF TREATMENTS ON FECAL MICROBIOTA AND FECAL METABOLIC PROFILING IN SYMPTOMATIC UNCOMPLICATED DIVERTICULAR DISEASE OF THE COLON
24. P.06.24 HISTOLOGICAL GHRELIN EXPRESSION CORRELATES WITH ECL PROLIFERATION AND CHROMOGRANIN A IMMUNOEXPRESSION: A COMPARATIVE STUDY BETWEEN ATROPHIC AND NON-ATROPHIC GASTRITIS
25. P.06.14 EFFECTIVENESS AND SAFETY OF PYLERA ® IN PATIENTS INFECTED BY HELICOBACTER PYLORI: A LARGE, PROSPECTIVE, REAL LIFE STUDY
26. P.05.7 EPIDEMIOLOGY OF DIVERTICULAR DISEASE OF THE COLON: A PRELIMINARY ANALYSIS FROM THE INTERNATIONAL “DICA” PROSPECTIVE STUDY
27. P.01.19 HOMOCYSTEINE IN CHRONIC ATROPHIC GASTRITIS: A STUDY ON IMMUNOHISTOCHEMICAL PATTERNS IN GASTRIC MUCOSA
28. P.02.5 SIX-YEAR EFFICACY AND SAFETY OF AZATHIOPRINE TREATMENT IN THE MAINTENANCE OF STEROID-FREE REMISSION IN INFLAMMATORY BOWEL DISEASE PATIENTS
29. P.06.30 RISK FACTORS FOR ONSET OF ESOPHAGITIS IN A LONG 15 YEARS FOLLOW-UP
30. OC.10.2: Fecal Microbiota, Fecal and Urinary Metabolic Profiling and Symptomatic Uncomplicated Diverticular Disease of the Colon
31. P.01.5: Serum Pepsinogen II as a Non-Invasive Marker for Diagnosis of Helicobacter Pylori Infection: A Prospective Study in a Cohort of Dyspeptic Patients
32. P.02.7: The Branded Proton Pump Inhibitors (PPIS) Increase Levels of Gastrin 17 (G-17) More than the Generic Ones in Dyspeptic Patients from an Italian Primary Care Population
33. P.11.1: Azathioprine in the Maintenance of Steroid-Free Remission in Inflammatory Bowel Disease Patients: Efficacy and Safety in Five Years of Follow-Up
34. P.07.2: Natural History of Symptomatic Uncomplicated Diverticular Disease: A 13-Year Prospective Study
35. P.07.7: Impact of Endoscopic Classification “Dica” on the Burden of Diverticular Disease of the Colon in Italy
36. P.07.13 FOUR-YEAR EFFICACY AND SAFETY OF AZATHIOPRINE TREATMENT IN THE MAINTAINANCE OF STEROID-FREE REMISSION IN INFLAMMATORY BOWEL DISEASE PATIENTS
37. P.09.12 ASSESSMENT OF FECAL MICROBIOTA AND FECAL METABOLOME IN SYMPTOMATIC UNCOMPLICATED DIVERTICULAR DISEASE OF THE COLON
38. PC.01.2 PREDICTIVE VALUE OF THE “DICA” ENDOSCOPIC CLASSIFICATION ON THE OUTCOME OF THE DIVERTICULAR DISEASE OF THE COLON: AN INTERNATIONAL STUDY
39. OC.05.5 DEVELOPMENT AND VALIDATION OF AN ENDOSCOPIC CLASSIFICATION OF DIVERTICULAR DISEASE OF THE COLON: THE DICA CLASSIFICATION
40. P.06.11 HISTOLOGICAL INFLAMMATION IN ULCERATIVE COLITIS IN DEEP REMISSION UNDER TREATMENT WITH INFLIXIMAB
41. P.06.25 INFLIXIMAB AND ADALIMUMAB FOR CROHN'S DISEASE IN REAL LIFE: EFFECTIVENESS, SAFETY AND ABILITY IN OBTAINING MUCOSAL AND HISTOLOGICAL HEALING
42. P.11.7 FECAL CALPROTECTIN IN PREDICTING RECURRENCE AFTER ATTACK OF COLONIC DIVERTICULITIS
43. P.11.6 MODERATE-TO-SEVERE AND PROLONGED LEFT LOWER ABDOMINAL PAIN IS THE BEST SYMPTOM CHARACTERIZING SYMPTOMATIC UNCOMPLICATED DIVERTICULAR DISEASE OF THE COLON: A COMPARISON WITH FECAL CALPROTECTIN IN CLINICAL SETTING
44. P.12.9 MESALAZINE AND/OR LACTOBACILLUS CASEI IN MAINTAINING REMISSION OF SYMPTOMATIC UNCOMPLICATED DIVERTICULAR DISEASE OF THE COLON: A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
45. P.12.12 INTERMITTENT VERSUS EVERY-DAY MESALAZINE THERAPY IN PREVENTING COMPLICATIONS OF DIVERTICULAR DISEASE OF THE COLON: A LONG-TERM FOLLOW-UP STUDY
46. P.12.10 MUCOSAL EXPRESSION OF BASIC FIBROBLASTIC GROWTH FACTOR, SYNDECAN 1 AND TUMOUR NECROSIS FACTOR-ALPHA IN DIVERTICULAR DISEASE OF THE COLON: A CASE-CONTROL STUDY
47. P.19.5 EFFICACY, TOLERABILITY AND FACTORS AFFECTING THE EFFICACY OF THE SEQUENTIAL THERAPY IN CURING HELICOBACTER PYLORI INFECTION IN CLINICAL SETTING
48. P.12.11 PERSISTENCE OF INFLAMMATION AFTER AN ATTACK OF COLONIC DIVERTICULITIS IS A RISK FACTOR OF DIVERTICULITIS RECURRENCE
49. P.12.9 MUCOSAL TUMOUR NECROSIS FACTOR-ALPHA IN DIVERTICULAR DISEASE OF THE COLON IS OVEREXPRESSED IN RELATION TO THE SEVERITY OF THE DISEASE
50. P.1.195: PERSISTENCE OF ENDOSCOPIC AND HISTOLOGICAL INFLAMMATION AFTER ATTACK OF COLONIC DIVERTICULITIS AS RISK FACTORS OF DIVERTICULITIS RECURRENCE
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.